(RTTNews) - Janux Therapeutics Inc. (JANX), a clinical-stage biopharmaceutical company, Thursday, priced an underwritten public offering of 5.32 million shares at $63.00 per share.
The pre-funded warrants to purchase 238,095 shares of common stock are priced at $62.999 per pre-funded warrant.
The underwriters have a 30-day option to purchase up to an additional 833,333 shares of the company's common stock.
The transaction, which is expected to rake in gross proceeds of $350.0 million, is slated to close on or by December 6, 2024, subject to certain conditions.
JANX closed yesterday's trading at $66.83, up 11.65%. In premarket trading today, the stock is up another 0.40% at $67.10.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
